Agenus Inc. (AGEN)
AGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$6.95
-6.46% on the day
Market cap
$313.9M
Small cap
Revenue · 2025
$114.2M
+10.4% on 2024
Net income · 2025
-$3.1M
-2.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | AGEN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2000 |
| SEC CIK | 0001098972 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $114.2M |
| Net income | -$3.1M |
| Operating income | -$20.2M |
| Net margin | -2.7% |
| Operating margin | -17.7% |
| Revenue growth | +10.4% |
| Cash | $3.0M |
| Total assets | $226.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-09-11 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-08-07 |
| Latest current report | 8-K | 2026-08-18 |
| Latest proxy | DEFA14A | 2026-05-13 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.1% |
| 1 month | -9.2% |
| 3 months | +30.0% |
| Year to date | +107.0% |
| 1 year | +60.5% |
| From 52-week high | -34.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARTV | Artiva Biotherapeutics Inc. | $6.29 | -7.09% | $307.5M |
| IRLA | IRulya Therapeutics Inc. | $27.87 | -13.98% | $302.2M |
| OCGN | Ocugen Inc. | $0.8854 | -6.52% | $300.2M |
| CCCC | C4 Therapeutics Inc. | $2.78 | -9.15% | $342.0M |
| CABA | Cabaletta Bio Inc. | $1.69 | -5.59% | $286.5M |
| SRZN | Surrozen Inc. | $23.51 | -5.05% | $276.3M |
| FENC | Fennec Pharmaceuticals Inc. | $10.18 | -5.04% | $356.6M |
| KYTX | Kyverna Therapeutics Inc. | $5.77 | -7.08% | $356.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier